Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jin Takeuchi

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
International Journal of Hematology|July 5, 2003
Prognostic significance of CD7+CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0Ritsuro Suzuki, Makoto Murata, Masahiro Kami, et al.
International Journal of Hematology|June 5, 2020
The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapseSaiko Kurosawa, Hiroki Yamaguchi, Takuhiro Yamaguchi, et al.
Annals of Hematology|April 26, 2018
Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALLYoshihiro Hatta, Shuichi Mizuta, Keitaro Matsuo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 5, 2016
Decision Analysis of Postremission Therapy in Cytogenetically Intermediate-Risk Acute Myeloid Leukemia: The Impact of FLT3 Internal Tandem Duplication, Nucleophosmin, and CCAAT/Enhancer Binding Protein AlphaSaiko Kurosawa, Hiroki Yamaguchi, Takuhiro Yamaguchi, et al.
International Journal of Hematology|April 11, 2009
Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative studyYukio Kobayashi, Kensei Tobinai, Akihiro Takeshita, et al.
Cancer|June 27, 2013
The demarcation between younger and older acute myeloid leukemia patients: a pooled analysis of 3 prospective studiesMasamitsu Yanada, Shigeki Ohtake, Shuichi Miyawaki, et al.
International Journal of Hematology|September 11, 2010
Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 studyItsuro Jinnai, Tohru Sakura, Motohiro Tsuzuki, et al.
Oncology Reports|November 21, 2012
Efficacy of a dose-intensified CHOP (Double-CHOP) regimen for peripheral T-cell lymphomasNoriyoshi Iriyama, Hiromichi Takahashi, Yoshihiro Hatta, et al.
British Journal of Haematology|November 7, 2008
Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapyMasamitsu Yanada, Isamu Sugiura, Jin Takeuchi, et al.
International Journal of Hematology|June 26, 2010
Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in JapanTadashi Nagai, Jin Takeuchi, Nobuaki Dobashi, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
International Journal of Hematology|July 5, 2003
Prognostic significance of CD7+CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0Ritsuro Suzuki, Makoto Murata, Masahiro Kami, et al.
International Journal of Hematology|June 5, 2020
The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapseSaiko Kurosawa, Hiroki Yamaguchi, Takuhiro Yamaguchi, et al.
Annals of Hematology|April 26, 2018
Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALLYoshihiro Hatta, Shuichi Mizuta, Keitaro Matsuo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 5, 2016
Decision Analysis of Postremission Therapy in Cytogenetically Intermediate-Risk Acute Myeloid Leukemia: The Impact of FLT3 Internal Tandem Duplication, Nucleophosmin, and CCAAT/Enhancer Binding Protein AlphaSaiko Kurosawa, Hiroki Yamaguchi, Takuhiro Yamaguchi, et al.
International Journal of Hematology|April 11, 2009
Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative studyYukio Kobayashi, Kensei Tobinai, Akihiro Takeshita, et al.
Cancer|June 27, 2013
The demarcation between younger and older acute myeloid leukemia patients: a pooled analysis of 3 prospective studiesMasamitsu Yanada, Shigeki Ohtake, Shuichi Miyawaki, et al.
International Journal of Hematology|September 11, 2010
Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 studyItsuro Jinnai, Tohru Sakura, Motohiro Tsuzuki, et al.
Oncology Reports|November 21, 2012
Efficacy of a dose-intensified CHOP (Double-CHOP) regimen for peripheral T-cell lymphomasNoriyoshi Iriyama, Hiromichi Takahashi, Yoshihiro Hatta, et al.
British Journal of Haematology|November 7, 2008
Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapyMasamitsu Yanada, Isamu Sugiura, Jin Takeuchi, et al.
International Journal of Hematology|June 26, 2010
Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in JapanTadashi Nagai, Jin Takeuchi, Nobuaki Dobashi, et al.
Pageof 7